Terms: = Endocrine gland cancer AND ER, estrogen receptor AND Clinical Outcome
37 results:
1. BRAF
Cao J; Chen B; Zhu X; Sun Y; Li X; Zhang W; Wang X
Endocrine; 2024 Apr; 84(1):160-170. PubMed ID: 37851243
[TBL] [Abstract] [Full Text] [Related]
2. Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy.
Wang C; Lu G; Li Y; Liu X; Wang G; Lu C; Li J; Luo Q; Zhang Q; Sun M; Wang X; Wang R
Front Endocrinol (Lausanne); 2023; 14():1217092. PubMed ID: 37600705
[TBL] [Abstract] [Full Text] [Related]
3. Nuclear receptor co-repressor NCOR2 and its relation to GPER with prognostic impact in ovarian cancer.
Reichenbach J; Fraungruber P; Mayr D; Buschmann C; Kraus FBT; Topalov NE; Chelariu-Raicu A; Kolben T; Burges A; Mahner S; Kessler M; Jeschke U; Czogalla B; Trillsch F
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8719-8728. PubMed ID: 37131060
[TBL] [Abstract] [Full Text] [Related]
4. PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification.
Zhang X; Wang A; Han L; Liang B; Allard G; Diver E; Howitt BE
Mod Pathol; 2023 May; 36(5):100106. PubMed ID: 36805789
[TBL] [Abstract] [Full Text] [Related]
5. Analysis of factors influencing the clinical outcome after surgery and
Li Y; Rao M; Zheng C; Huang J; Fang D; Xiong Y; Yuan G
Front Endocrinol (Lausanne); 2022; 13():1015798. PubMed ID: 36313750
[TBL] [Abstract] [Full Text] [Related]
6. estrogen receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term outcome in Postmenopausal Patients with endocrine-Responsive Early Breast cancer.
Singer CF; ; Holst F; Steurer S; Burandt EC; Lax SF; Jakesz R; Rudas M; Stöger H; Greil R; ; Sauter G; Filipits M; ; Simon R; Gnant M;
Clin Cancer Res; 2022 Sep; 28(18):4112-4120. PubMed ID: 35920686
[TBL] [Abstract] [Full Text] [Related]
7. Potential Impact of Body Mass Index on the clinical outcome of Papillary Thyroid cancer After High-Dose Radioactive Iodine Therapy.
Cao J; Zhu X; Sun Y; Li X; Yun C; Zhang W
Front Endocrinol (Lausanne); 2022; 13():870530. PubMed ID: 35721759
[TBL] [Abstract] [Full Text] [Related]
8. Significance of ERCC1 and Hormonal receptor Expression in Ovarian cancer.
El-Moniem Elrawi DA; El Khodary AI; Nassar HR; Darwish AD; Khorshed EN
J Med Invest; 2020; 67(3.4):391-398. PubMed ID: 33148925
[TBL] [Abstract] [Full Text] [Related]
9. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma.
Wen C; Deng X; Ren D; Song X; Chen H; Wang J; Jin J; Cheng D; Xu Z; Zhang J; Xie J; Qi W; Gu J; Peng C; Chen D; Chen S; Shen B; Zhan Q
Cancer Med; 2020 Oct; 9(20):7626-7636. PubMed ID: 32862515
[TBL] [Abstract] [Full Text] [Related]
10. Clinicopathological significance of endoplasmic reticulum stress proteins in ovarian carcinoma.
Samanta S; Tamura S; Dubeau L; Mhawech-Fauceglia P; Miyagi Y; Kato H; Lieberman R; Buckanovich RJ; Lin YG; Neamati N
Sci Rep; 2020 Feb; 10(1):2160. PubMed ID: 32034256
[TBL] [Abstract] [Full Text] [Related]
11. Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma.
Hollis RL; Stanley B; Iida Y; Thomson J; Churchman M; Rye T; Mackean M; Nussey F; Gourley C; Herrington CS
Gynecol Oncol; 2019 Nov; 155(2):318-323. PubMed ID: 31495455
[TBL] [Abstract] [Full Text] [Related]
12. ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.
Cao Y; Trillo-Tinoco J; Sierra RA; Anadon C; Dai W; Mohamed E; Cen L; Costich TL; Magliocco A; Marchion D; Klar R; Michel S; Jaschinski F; Reich RR; Mehrotra S; Cubillos-Ruiz JR; Munn DH; Conejo-Garcia JR; Rodriguez PC
Nat Commun; 2019 Mar; 10(1):1280. PubMed ID: 30894532
[TBL] [Abstract] [Full Text] [Related]
13. ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer.
Giannopoulou L; Mastoraki S; Buderath P; Strati A; Pavlakis K; Kasimir-Bauer S; Lianidou ES
Gynecol Oncol; 2018 Aug; 150(2):355-360. PubMed ID: 29807696
[TBL] [Abstract] [Full Text] [Related]
14. Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer.
Li H; Zhang YQ; Wang C; Zhang X; Li X; Lin YS
Clin Endocrinol (Oxf); 2018 Apr; 88(4):601-606. PubMed ID: 29338092
[TBL] [Abstract] [Full Text] [Related]
15. WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response.
Janczar S; Nautiyal J; Xiao Y; Curry E; Sun M; Zanini E; Paige AJ; Gabra H
Cell Death Dis; 2017 Jul; 8(7):e2955. PubMed ID: 28749468
[TBL] [Abstract] [Full Text] [Related]
16. The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
George A; McLachlan J; Tunariu N; Della Pepa C; Migali C; Gore M; Kaye S; Banerjee S
BMC Cancer; 2017 Jun; 17(1):456. PubMed ID: 28666422
[TBL] [Abstract] [Full Text] [Related]
17. clinical outcome of Radioiodine Therapy in Low-intermediate Risk Papillary Thyroid Carcinoma with BRAF(V600E) Mutation.
Li J; Yang T; Zhao T; Liang J; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Jun; 38(3):346-50. PubMed ID: 27544995
[TBL] [Abstract] [Full Text] [Related]
18. clinical outcome of (131)I Therapy in Differentiated Thyroid cancer with Preablative Thyroglobulin below 10 ng/ml.
Liu XF; Li J; Zhao T; Hou M; Li H; Liang J; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Feb; 38(1):88-92. PubMed ID: 26956863
[TBL] [Abstract] [Full Text] [Related]
19. Complex formation and function of estrogen receptor α in transcription requires RIP140.
Rosell M; Nevedomskaya E; Stelloo S; Nautiyal J; Poliandri A; Steel JH; Wessels LF; Carroll JS; Parker MG; Zwart W
Cancer Res; 2014 Oct; 74(19):5469-79. PubMed ID: 25145671
[TBL] [Abstract] [Full Text] [Related]
20. estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK
Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832
[TBL] [Abstract] [Full Text] [Related]
[Next]
